Based on the amazing takeover that Paul Hopper (Chairman of IMU & VLA) was able to engineer for his other biotech baby today - with Merck & Co taking over VLA (and paying VLA shareholders a share price premium of 160%!!!!!) it seems logical that at some point in the future, assuming continued positive progress of our Herr-Vaxx, Mimitope & Arginine Modulator trials, that he will also seek to orchestrate a takeover of IMU by Merck.
Not to be outdone however, our esteemed IMU Director Mr Axel Hoos (Vice President, Oncology R&D at GlaxoSmithKline) will no doubt kindly generate some competitive tension in the bidding process by ensuring an alternate offer is put forward for IMU by GSK.
Whilst I appreciate it is early days, I am patient and supremely confident when I say that at some point in the next 12 months - LET THE BIDDIG WAR COMMENCE!!!
IMU Price at posting:
2.2¢ Sentiment: Buy Disclosure: Held
